Sellas to present new preclinical SLS009 data for pancreatic cancer
Sellas Life Sciences said three abstracts for SLS009 (Tambiciclib) have been accepted for poster presentation at a major oncology conference.
Sellas Life Sciences (SLS) was in the spotlight on Wednesday after the retail-favorite biotech firm said it will present new preclinical data on its experimental drug SLS009 to treat pancreatic cancer.Three abstracts evaluating SLS009, also known as Tambiciclib, have been accepted for poster presen…